Negotiating Clinical Trial Agreements
This article was originally published in RAJ Devices
Katherine Leibowitz and Victoria Sheckler report on some of the key provisions that should be included in sponsor-initiated clinical trial agreements in the US.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.